Automate Your Wheel Strategy on INO
With Tiblio's Option Bot, you can configure your own wheel strategy including INO - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol INO
- Rev/Share 0.0047
- Book/Share 0.7348
- PB 3.6678
- Debt/Equity 0.3736
- CurrentRatio 1.662
- ROIC -2.4459
- MktCap 143219577.0
- FreeCF/Share -3400.9801
- PFCF -0.0011
- PE -0.0023
- Debt/Assets 0.1562
- DivYield 0
- ROE -809.7
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 4
- P/B Score 2
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | INO | Piper Sandler | -- | Overweight | -- | $5 | July 9, 2025 |
News
Inovio Pharmaceuticals, Inc. (INO) Presents At H.C. Wainwright 27th Annual Global Investment Conference (Transcript)
Published: September 05, 2025 by: Seeking Alpha
Sentiment: Neutral
Inovio Pharmaceuticals, Inc. (NASDAQ:INO ) H.C. Wainwright 27th Annual Global Investment Conference September 5, 2025 7:00 AM EDT Company Participants Jacqueline Shea - CEO, President & Director Conference Call Participants Katherine Degen Presentation Katherine Degen Good morning, and welcome to the H.C.
Read More
INO Stock Soars as FDA Backs Rolling BLA for Rare Lung Disease Drug
Published: August 28, 2025 by: Zacks Investment Research
Sentiment: Positive
Inovio stock surges 21% after the FDA gives green light to begin a rolling BLA for its RRP drug INO-3107, with plans to seek priority review.
Read More
3 Biotech Stocks Likely to Outpace Q2 Earnings Estimates
Published: August 11, 2025 by: Zacks Investment Research
Sentiment: Positive
Zevra, Inovio and Journey Medical are set for potential earnings beat this week, backed by strong products and positive ESP scores.
Read More
Data Published in The Laryngoscope shows INO-3107 Resulted in Long-Term Surgery Reduction in Recurrent Respiratory Papillomatosis (RRP)
Published: August 11, 2025 by: PRNewsWire
Sentiment: Neutral
Retrospective trial showed Overall Response Rate (ORR) improved to 86% at the end of the second 12-month period (Year 2) compared to 72% observed at the end of the initial 12-month Phase 1/2 trial (Year 1); the Complete Response (CR) rate improved to 50% for Year 2 from 28% for Year 1 Mean number of surgeries patients needed to control their RRP continued to drop from 4.1 surgeries per year prior to receiving INO-3107 to 1.7 for Year 1 to 0.9 for Year 2 Partial data into the third 12-month period (Year 3 - median follow up 2.8 years following …
Read More
Inovio Pharmaceuticals (INO) Expected to Beat Earnings Estimates: Should You Buy?
Published: August 05, 2025 by: Zacks Investment Research
Sentiment: Positive
Inovio (INO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
INOVIO Announces Proposed Public Offering
Published: July 02, 2025 by: PRNewsWire
Sentiment: Neutral
PLYMOUTH MEETING, Pa. , July 2, 2025 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it intends to offer and sell shares of its common stock (or pre-funded warrants to purchase its common stock in lieu thereof) and in either case, accompanying Series A warrants and Series B warrants to purchase shares of its common stock (or pre-funded warrants to purchase its common stock in lieu thereof), in an underwritten public offering.
Read More
INOVIO to Present at Upcoming Scientific and Investor Conferences
Published: April 30, 2025 by: PRNewsWire
Sentiment: Neutral
PLYMOUTH MEETING, Pa. , April 30, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it will be presenting at several upcoming conferences, including a fireside chat at the Citizens JMP Life Sciences Conference in New York.
Read More
Bet on These 5 Top-Ranked Stocks With Rising P/E
Published: April 21, 2025 by: Zacks Investment Research
Sentiment: Positive
Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks include Carvana, Context Therapeutics Inc, Inovio Pharmaceuticals, ChargePoint and MSA Safety Inc.
Read More
Inovio (INO) Upgraded to Buy: Here's What You Should Know
Published: April 09, 2025 by: Zacks Investment Research
Sentiment: Positive
Inovio (INO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Read More
INOVIO to Report Fourth Quarter and Year End 2024 Financial Results on March 18, 2025
Published: March 12, 2025 by: PRNewsWire
Sentiment: Neutral
PLYMOUTH MEETING, Pa. , March 12, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancers, and infectious diseases, today announced that fourth quarter and year-end 2024 financial results will be released after the market close on March 18, 2025.
Read More
Inovio Pharmaceuticals Inc (INO) Oppenheimer 35th Annual Healthcare Life Sciences Conference (Transcript)
Published: February 12, 2025 by: Seeking Alpha
Sentiment: Neutral
Inovio Pharmaceuticals Inc (NASDAQ:INO ) Oppenheimer 35th Annual Healthcare Life Sciences Conference February 12, 2025 3:20 PM ET Company Participants Jacqui Shea - CEO and President Conference Call Participants Jay Olson - Oppenheimer Jay Olson And our discussion with Inovio. It's a pleasure to introduce Jacqui Shea, CEO and President.
Read More
Here's Why Inovio (INO) Could be Great Choice for a Bottom Fisher
Published: February 12, 2025 by: Zacks Investment Research
Sentiment: Neutral
Inovio (INO) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Read More
Clinical and Immunological Results from Phase 1/2 Study of INO-3107 as a Treatment for Recurrent Respiratory Papillomatosis Published in Nature Communications
Published: February 12, 2025 by: PRNewsWire
Sentiment: Neutral
Data shows that INO-3107 induced new populations of T cells in the blood that traveled to airway tissue and were associated with clinical benefit as measured by reduced need for surgeries PLYMOUTH MEETING, Pa. , Feb. 12, 2025 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that peer-reviewed data from its Phase 1/2 clinical trial with INO-3107 as a potential treatment for recurrent respiratory papillomatosis (RRP) were published online in Nature Communications under the title DNA immunotherapy for …
Read More
About Inovio Pharmaceuticals, Inc. (INO)
- IPO Date 1998-12-08
- Website https://www.inovio.com
- Industry Biotechnology
- CEO Jacqueline E. Shea
- Employees 134